Integra LifeSciences Holdings Corporation — FY2023 Form 10-K Summary
Business context and reporting period
Integra is a global medical technology company selling products in more than 130 countries through two reportable segments: Codman Specialty Surgical (CSS), focused on neurosurgery, neurocritical care, instruments and related technologies; and Tissue Technologies (TT), focused on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The filing covers the fiscal year ended December 31, 2023, with comparisons primarily to fiscal 2022. The filing is an annual report rather than a standalone fourth-quarter filing.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $1,541.6 million | $1,557.7 million | Down 1.0% |
| Gross profit | $884.7 million | $970.3 million | Down $85.6 million |
| Gross margin | 57.4% | 62.3% | Down 490 basis points |
| Operating income | $111.5 million | $238.9 million | Down 53.3% |
| Net income | $67.7 million | $180.6 million | Down 62.5% |
| Diluted EPS | $0.84 | $2.16 | Down 61.1% |
| Operating cash flow | $140.0 million | $264.5 million | Down $124.5 million |
| Capital expenditures | $66.9 million | $42.3 million | Up $24.5 million |
CSS revenue increased 3.9% to $1,059.0 million, driven primarily by growth in neurosurgery and instruments. TT revenue declined 10.3% to $482.6 million, principally reflecting the Boston recall and related manufacturing disruption, the divestiture of the traditional wound care business, and foreign exchange effects. Excluding disclosed recall, divestiture, acquisition and currency effects, management reported growth in both domestic and international revenue.
Research and development expense was $104.2 million, or 6.8% of revenue, compared with 6.5% in 2022. Selling, general and administrative expense was $656.6 million, or 42.6% of revenue, compared with 39.6%. Income before taxes was $81.1 million and the effective tax rate was 16.4%.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $276.4 million at December 31, 2023, compared with $456.7 million at year-end 2022. Short-term investments were $32.7 million.
- Working capital was $751.1 million, down from $840.6 million.
- Total consolidated external debt was approximately $1.4 billion, consisting primarily of $789.5 million outstanding under the Senior Credit Facility, $89.2 million under the securitization facility, and $575.0 million principal amount of 0.5% convertible senior notes due 2025.
- The amended Senior Credit Facility provides approximately $2.1 billion of aggregate capacity, including a $775.0 million term loan and a $1.3 billion revolving facility, and matures March 24, 2028. The company was in compliance with its debt covenants at year-end.
- Net cash used in financing activities was $229.9 million, including $275.0 million of accelerated share repurchases and net debt repayments.
- The company believes cash and available borrowings are sufficient to fund operations and capital expenditures for the next twelve months. No cash dividends have been paid since formation.
Material changes versus the prior comparable period
- The Boston manufacturing disruption materially affected TT results. Integra recorded a $18.7 million provision for product returns, a $24.6 million inventory write-off, and total Boston recall expenses of $40.0 million, including idle-capacity charges.
- Boston facility products represented approximately 5.3% of consolidated revenue in 2022. Manufacturing resumed in the fourth quarter of 2023, but commercialization was targeted for the second half of 2024, subject to regulatory remediation.
- Total special charges increased to $134.8 million from $49.4 million, including $46.6 million of EU Medical Device Regulation costs, $40.0 million of Boston recall expenses, $23.0 million of structural optimization charges, and $25.2 million of acquisition, divestiture and integration-related charges.
- Operating cash flow fell substantially, while inventory increased to $389.6 million from $324.6 million, partly reflecting supply-chain and safety-stock considerations.
- The company completed $275.0 million of accelerated share repurchases during 2023 and held 12.8 million treasury shares at year-end. A separate repurchase program had $100.0 million remaining authorization as of December 31, 2023.
- Interest expense increased to $51.4 million, primarily because of incremental revolving borrowings and higher interest rates.
Guidance, outlook, commentary and unusual items
- Management estimated a 2024 effective tax rate of approximately 19.8% based on existing tax laws.
- Management expected to submit a final external audit concerning the Boston facility to the FDA by the end of the first quarter of 2024, with commercialization of affected products targeted for the second half of 2024. The filing states that the FDA may take further action if remediation is not satisfactory.
- Integra received FDA 510(k) clearance for CereLink in February 2024 and planned to resume U.S. shipments in the first quarter of 2024. International shipments had resumed on a limited basis in the third quarter of 2023.
- Integra expected its $275.0 million Acclarent acquisition from Johnson & Johnson to close by the second quarter of 2024, subject to regulatory approvals and customary conditions. An additional $5.0 million may be payable upon achievement of a regulatory milestone.
- The company completed enrollment in the DuraSorb clinical study and expects potential FDA approvals for DuraSorb and SurgiMend breast-reconstruction indications in 2025, although approval timing is uncertain.
- Expected annual amortization expense was approximately $82.7 million in 2024 and $82.7 million in 2025, declining gradually thereafter.
- Key risks include FDA and foreign regulatory compliance, remediation of Boston quality-system matters, product recalls, reimbursement and pricing pressure, supply-chain disruption, foreign currency and interest-rate exposure, acquisition integration, leverage, litigation, cybersecurity, and potential impairment of goodwill or intangible assets.
- As of December 31, 2023, the company reported no material cybersecurity incidents and management concluded that disclosure controls and internal control over financial reporting were effective. PwC issued unqualified opinions on the financial statements and internal control.
Most important facts for investors to verify
- Whether the FDA accepts Integra’s Boston remediation and whether commercialization actually resumes in the second half of 2024.
- The remaining financial impact of Boston product returns, inventory losses, customer credits and potential additional regulatory actions.
- The closing, financing and integration of the Acclarent acquisition and the effect of any regulatory conditions or divestitures.
- Whether CSS growth continues and whether TT revenue returns toward pre-recall levels.
- Progress toward the anticipated 2025 PMA approvals for SurgiMend and DuraSorb and the related contingent consideration exposure, which could reach up to $90.0 million for SIA-related milestones.
- Debt maturities and refinancing requirements, particularly the $575.0 million convertible notes due August 2025, as well as compliance with leverage covenants.
- The ACell earnout arbitration filed by Fortis Advisors and the securities class action concerning Boston quality-system disclosures and Tissue Technologies forecasts.
- Sensitivity of goodwill and intangible asset valuations to TT recovery assumptions, revenue growth, discount rates and continued market acceptance.